LBT INNOVATIONS LIMITED - Announcements

Market Cap $21.47M Add to my watchlist

Healthcare Medical Devices

LBT Innovations is a ground-breaking designer of advanced technology solutions for the... LBT Innovations is a ground-breaking designer of advanced technology solutions for the medical industry. We specialise in combining artificial intelligence, image analysis and software engineering to improve healthcare delivery. Our product, APAS® Independence, is a global first solution for automated reading of microbiology culture plates.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

LBT	Appendix 4E	PRICE SENSITIVE	29/08/24	123.77KB	Share
LBT	ASTRAZENECA SALE & SERVICE CONTRACT UP TO A$4.1M	PRICE SENSITIVE	07/08/24	125.99KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/24	396.98KB	Share
LBT	Response to ASX Price Query	PRICE SENSITIVE	14/06/24	283.04KB	Share
LBT	Lift of Pause in Trading	PRICE SENSITIVE	13/06/24	85.41KB	Share
LBT	Pause in Trading	PRICE SENSITIVE	13/06/24	114.48KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	330.74KB	Share
LBT	APAS PHARMAQC SALE TO NOVACINA	PRICE SENSITIVE	29/04/24	125.89KB	Share
LBT	APAS PharmaQC Commercially Ready - Performance Finalised	PRICE SENSITIVE	13/03/24	164.33KB	Share
LBT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/24	762.57KB	Share
LBT	Delivery Completes First Sale of APAS PharmaQC	PRICE SENSITIVE	22/02/24	116.03KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/01/24	298.61KB	Share
LBT	Placement Completes Financial Restructure	PRICE SENSITIVE	20/11/23	132.13KB	Share
LBT	Renounceable Rights Issue Results	PRICE SENSITIVE	15/11/23	119.95KB	Share
LBT	$1.7M SA Government Loan Restructure	PRICE SENSITIVE	06/11/23	148.64KB	Share
LBT	Entitlement Offer Underwriting Increased to $3.6M	PRICE SENSITIVE	27/10/23	81.08KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/23	385.09KB	Share
LBT	Prospectus	PRICE SENSITIVE	13/10/23	788.16KB	Share
LBT	$4.5 million Entitlement Offer	PRICE SENSITIVE	13/10/23	148.04KB	Share
LBT	Full Repayment of $1.38M Share Placement Facility	PRICE SENSITIVE	13/10/23	114.6KB	Share
LBT	Preliminary Annual Financial Report & Appendix 4E	PRICE SENSITIVE	31/08/23	899.3KB	Share
LBT	Non-Cash Impairment of Intangible Assets	PRICE SENSITIVE	04/08/23	116.2KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	351.93KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	365.77KB	Share
LBT	Placement Supports APAS Pharma & EU Expansion	PRICE SENSITIVE	20/03/23	174.43KB	Share
LBT	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.17MB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/01/23	463.53KB	Share
LBT	AstraZeneca Partners LBT for APAS Pharma Development	PRICE SENSITIVE	09/01/23	117.2KB	Share
LBT	LBT Strengthens APAS Pharma Development	PRICE SENSITIVE	20/12/22	110.44KB	Share
LBT	CCS Appoint Thermo Fisher as Exclusive European Distributor	PRICE SENSITIVE	19/12/22	115.88KB	Share
LBT	Non-renounceable Rights Issue Results	PRICE SENSITIVE	28/11/22	114.71KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	456.94KB	Share
LBT	Rights Issue Prospectus	PRICE SENSITIVE	25/10/22	630.34KB	Share
LBT	Non-Renounceable Rights Issue	PRICE SENSITIVE	25/10/22	198.85KB	Share
LBT	$1.5M Funding Awarded for New APAS Instrument	PRICE SENSITIVE	24/10/22	207.89KB	Share
LBT	Appendix 4E	PRICE SENSITIVE	29/08/22	126.33KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	284.83KB	Share
LBT	Direct Sale of APAS Independence in United States	PRICE SENSITIVE	03/05/22	174.44KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	451.86KB	Share
LBT	Purchase Order for Multiple APAS Instruments	PRICE SENSITIVE	16/03/22	154.35KB	Share
LBT	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	948.1KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	357.01KB	Share
LBT	LBT Investor Call to discuss CCS Acquisition	PRICE SENSITIVE	11/01/22	995.92KB	Share
LBT	LBT Completes CCS Acquisition	PRICE SENSITIVE	04/01/22	131.87KB	Share
LBT	LBT to Obtain Full Ownership of CCS Joint Venture	PRICE SENSITIVE	29/12/21	146.74KB	Share
LBT	Market Update - Sales Pipeline and Evaluations	PRICE SENSITIVE	08/12/21	163.72KB	Share
LBT	US FDA 510(k) Clearance for MRSA Analysis Module	PRICE SENSITIVE	29/10/21	335.82KB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	444.4KB	Share
LBT	CCS Appoints Thermo Fisher as Exclusive US APAS Distributor	PRICE SENSITIVE	27/09/21	185.99KB	Share
LBT	Appendix 4E and Annual Financial Statements	PRICE SENSITIVE	26/08/21	1.49MB	Share
LBT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	335.85KB	Share
LBT	APAS Independence Sales to Health Services Laboratory, UK	PRICE SENSITIVE	18/05/21	128.66KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/21	368.76KB	Share
LBT	Half Yearly Report and Accounts	PRICE SENSITIVE	19/02/21	822.04KB	Share
LBT	Market Update - Board Renewal Process	PRICE SENSITIVE	01/02/21	123.51KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	348.28KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/20	352.13KB	Share
LBT	$0.75m Funding Awarded for APAS-AMR Analysis Module	PRICE SENSITIVE	03/09/20	584.65KB	Share
LBT	Appendix 4E	PRICE SENSITIVE	27/08/20	122.55KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/20	378.29KB	Share
LBT	Oneservice Appointed Managed Service Provider for APAS	PRICE SENSITIVE	13/07/20	145.38KB	Share
LBT	Proposed issue of Securities - LBT	PRICE SENSITIVE	09/07/20	34.63KB	Share
LBT	$8M PRIVATE PLACEMENT & LAUNCH OF SPP	PRICE SENSITIVE	09/07/20	1.56MB	Share
LBT	Trading Halt	PRICE SENSITIVE	07/07/20	338.52KB	Share
LBT	Pause in Trading	PRICE SENSITIVE	07/07/20	115.04KB	Share
LBT	LBT TEAMS WITH GLOBAL CLINICAL DIAGNOSTICS COMPANY	PRICE SENSITIVE	07/07/20	316KB	Share
LBT	Results of Evaluation of APAS Independence by Johns Hopkins	PRICE SENSITIVE	30/06/20	451.88KB	Share
LBT	First Sale of APAS Independence in United States	PRICE SENSITIVE	09/06/20	135.7KB	Share
LBT	Update on MRSA Analysis Module US FDA Submission	PRICE SENSITIVE	04/06/20	164.71KB	Share
LBT	$1.5M Draw Down on South Australian Government Loan	PRICE SENSITIVE	26/05/20	145.68KB	Share
LBT	South Australian Government Agree to Extend Loan Facility	PRICE SENSITIVE	08/05/20	131.29KB	Share
LBT	Presentation at NWR Virtual Small Cap Conference	PRICE SENSITIVE	30/04/20	1.42MB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/20	343.93KB	Share
LBT	US FDA 510(k) Submission for MRSA Analysis Module	PRICE SENSITIVE	30/03/20	136.56KB	Share
LBT	VRE Analysis Module - Clinical Study Commenced	PRICE SENSITIVE	19/03/20	135.38KB	Share
LBT	Johns Hopkins Hosp to Present Study Data APAS Independence	PRICE SENSITIVE	12/03/20	155.67KB	Share
LBT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	755.69KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/20	323.01KB	Share
LBT	LBT Receives $1.1 Million R&D Tax Incentive	PRICE SENSITIVE	22/01/20	101.73KB	Share
LBT	Presentation at Biotech Showcase Investor Conference	PRICE SENSITIVE	14/01/20	1.52MB	Share
LBT	CEO Presentation - AGM 2019	PRICE SENSITIVE	27/11/19	1.42MB	Share
LBT	Chairman's Address to Shareholders	PRICE SENSITIVE	27/11/19	109.92KB	Share
LBT	Non-Executive Director Retirement	PRICE SENSITIVE	30/10/19	128.69KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/19	298.57KB	Share
LBT	First European Sale of APAS Independence	PRICE SENSITIVE	21/10/19	145.61KB	Share
LBT	LBT Presents at ExchangeSA Conference in Adelaide	PRICE SENSITIVE	26/09/19	2.31MB	Share
LBT	MRSA Analysis Module CE Mark Registration	PRICE SENSITIVE	25/09/19	133.87KB	Share
LBT	European Union Regulatory Certification & MRSA Study Results	PRICE SENSITIVE	16/09/19	145.9KB	Share
LBT	Appendix 4E Full Year Report	PRICE SENSITIVE	29/08/19	141.14KB	Share
LBT	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/19	291.44KB	Share
LBT	Update on Distributor Appointments	PRICE SENSITIVE	22/07/19	140.02KB	Share
LBT	South Australian Government Loan $1.5M Drawdown	PRICE SENSITIVE	27/06/19	131.69KB	Share
LBT	First U.S. Clinical Data with APAS Presented at ASM Microbe	PRICE SENSITIVE	24/06/19	658.03KB	Share
LBT	US Market Update	PRICE SENSITIVE	19/06/19	132.39KB	Share
LBT	Information Required Under ASX Listing Rule 3.10.5A	PRICE SENSITIVE	11/06/19	111.28KB	Share
LBT	$5M Oversubscribed Private Placement	PRICE SENSITIVE	05/06/19	1.46MB	Share
LBT	Trading Halt	PRICE SENSITIVE	03/06/19	292.92KB	Share
LBT	APAS Independence Receives US FDA 510(k) Clearance	PRICE SENSITIVE	20/05/19	442.5KB	Share
LBT	Trading Halt	PRICE SENSITIVE	17/05/19	157.96KB	Share
LBT	South Australian Government Loan - $1.0M Drawdown	PRICE SENSITIVE	09/05/19	130.71KB	Share

LBT Appendix 4E
29/08/24	PRICE SENSITIVE	123.77KB	Share
LBT ASTRAZENECA SALE & SERVICE CONTRACT UP TO A$4.1M
07/08/24	PRICE SENSITIVE	125.99KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
25/07/24	PRICE SENSITIVE	396.98KB	Share
LBT Response to ASX Price Query
14/06/24	PRICE SENSITIVE	283.04KB	Share
LBT Lift of Pause in Trading
13/06/24	PRICE SENSITIVE	85.41KB	Share
LBT Pause in Trading
13/06/24	PRICE SENSITIVE	114.48KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	330.74KB	Share
LBT APAS PHARMAQC SALE TO NOVACINA
29/04/24	PRICE SENSITIVE	125.89KB	Share
LBT APAS PharmaQC Commercially Ready - Performance Finalised
13/03/24	PRICE SENSITIVE	164.33KB	Share
LBT Half Yearly Report and Accounts
23/02/24	PRICE SENSITIVE	762.57KB	Share
LBT Delivery Completes First Sale of APAS PharmaQC
22/02/24	PRICE SENSITIVE	116.03KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
22/01/24	PRICE SENSITIVE	298.61KB	Share
LBT Placement Completes Financial Restructure
20/11/23	PRICE SENSITIVE	132.13KB	Share
LBT Renounceable Rights Issue Results
15/11/23	PRICE SENSITIVE	119.95KB	Share
LBT $1.7M SA Government Loan Restructure
06/11/23	PRICE SENSITIVE	148.64KB	Share
LBT Entitlement Offer Underwriting Increased to $3.6M
27/10/23	PRICE SENSITIVE	81.08KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
26/10/23	PRICE SENSITIVE	385.09KB	Share
LBT Prospectus
13/10/23	PRICE SENSITIVE	788.16KB	Share
LBT $4.5 million Entitlement Offer
13/10/23	PRICE SENSITIVE	148.04KB	Share
LBT Full Repayment of $1.38M Share Placement Facility
13/10/23	PRICE SENSITIVE	114.6KB	Share
LBT Preliminary Annual Financial Report & Appendix 4E
31/08/23	PRICE SENSITIVE	899.3KB	Share
LBT Non-Cash Impairment of Intangible Assets
04/08/23	PRICE SENSITIVE	116.2KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	351.93KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	365.77KB	Share
LBT Placement Supports APAS Pharma & EU Expansion
20/03/23	PRICE SENSITIVE	174.43KB	Share
LBT Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.17MB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
23/01/23	PRICE SENSITIVE	463.53KB	Share
LBT AstraZeneca Partners LBT for APAS Pharma Development
09/01/23	PRICE SENSITIVE	117.2KB	Share
LBT LBT Strengthens APAS Pharma Development
20/12/22	PRICE SENSITIVE	110.44KB	Share
LBT CCS Appoint Thermo Fisher as Exclusive European Distributor
19/12/22	PRICE SENSITIVE	115.88KB	Share
LBT Non-renounceable Rights Issue Results
28/11/22	PRICE SENSITIVE	114.71KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	456.94KB	Share
LBT Rights Issue Prospectus
25/10/22	PRICE SENSITIVE	630.34KB	Share
LBT Non-Renounceable Rights Issue
25/10/22	PRICE SENSITIVE	198.85KB	Share
LBT $1.5M Funding Awarded for New APAS Instrument
24/10/22	PRICE SENSITIVE	207.89KB	Share
LBT Appendix 4E
29/08/22	PRICE SENSITIVE	126.33KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	284.83KB	Share
LBT Direct Sale of APAS Independence in United States
03/05/22	PRICE SENSITIVE	174.44KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	451.86KB	Share
LBT Purchase Order for Multiple APAS Instruments
16/03/22	PRICE SENSITIVE	154.35KB	Share
LBT Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	948.1KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	357.01KB	Share
LBT LBT Investor Call to discuss CCS Acquisition
11/01/22	PRICE SENSITIVE	995.92KB	Share
LBT LBT Completes CCS Acquisition
04/01/22	PRICE SENSITIVE	131.87KB	Share
LBT LBT to Obtain Full Ownership of CCS Joint Venture
29/12/21	PRICE SENSITIVE	146.74KB	Share
LBT Market Update - Sales Pipeline and Evaluations
08/12/21	PRICE SENSITIVE	163.72KB	Share
LBT US FDA 510(k) Clearance for MRSA Analysis Module
29/10/21	PRICE SENSITIVE	335.82KB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	444.4KB	Share
LBT CCS Appoints Thermo Fisher as Exclusive US APAS Distributor
27/09/21	PRICE SENSITIVE	185.99KB	Share
LBT Appendix 4E and Annual Financial Statements
26/08/21	PRICE SENSITIVE	1.49MB	Share
LBT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	335.85KB	Share
LBT APAS Independence Sales to Health Services Laboratory, UK
18/05/21	PRICE SENSITIVE	128.66KB	Share
LBT Appendix 4C - quarterly
29/04/21	PRICE SENSITIVE	368.76KB	Share
LBT Half Yearly Report and Accounts
19/02/21	PRICE SENSITIVE	822.04KB	Share
LBT Market Update - Board Renewal Process
01/02/21	PRICE SENSITIVE	123.51KB	Share
LBT Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	348.28KB	Share
LBT Appendix 4C - quarterly
27/10/20	PRICE SENSITIVE	352.13KB	Share
LBT $0.75m Funding Awarded for APAS-AMR Analysis Module
03/09/20	PRICE SENSITIVE	584.65KB	Share
LBT Appendix 4E
27/08/20	PRICE SENSITIVE	122.55KB	Share
LBT Appendix 4C - quarterly
29/07/20	PRICE SENSITIVE	378.29KB	Share
LBT Oneservice Appointed Managed Service Provider for APAS
13/07/20	PRICE SENSITIVE	145.38KB	Share
LBT Proposed issue of Securities - LBT
09/07/20	PRICE SENSITIVE	34.63KB	Share
LBT $8M PRIVATE PLACEMENT & LAUNCH OF SPP
09/07/20	PRICE SENSITIVE	1.56MB	Share
LBT Trading Halt
07/07/20	PRICE SENSITIVE	338.52KB	Share
LBT Pause in Trading
07/07/20	PRICE SENSITIVE	115.04KB	Share
LBT LBT TEAMS WITH GLOBAL CLINICAL DIAGNOSTICS COMPANY
07/07/20	PRICE SENSITIVE	316KB	Share
LBT Results of Evaluation of APAS Independence by Johns Hopkins
30/06/20	PRICE SENSITIVE	451.88KB	Share
LBT First Sale of APAS Independence in United States
09/06/20	PRICE SENSITIVE	135.7KB	Share
LBT Update on MRSA Analysis Module US FDA Submission
04/06/20	PRICE SENSITIVE	164.71KB	Share
LBT $1.5M Draw Down on South Australian Government Loan
26/05/20	PRICE SENSITIVE	145.68KB	Share
LBT South Australian Government Agree to Extend Loan Facility
08/05/20	PRICE SENSITIVE	131.29KB	Share
LBT Presentation at NWR Virtual Small Cap Conference
30/04/20	PRICE SENSITIVE	1.42MB	Share
LBT Appendix 4C - quarterly
28/04/20	PRICE SENSITIVE	343.93KB	Share
LBT US FDA 510(k) Submission for MRSA Analysis Module
30/03/20	PRICE SENSITIVE	136.56KB	Share
LBT VRE Analysis Module - Clinical Study Commenced
19/03/20	PRICE SENSITIVE	135.38KB	Share
LBT Johns Hopkins Hosp to Present Study Data APAS Independence
12/03/20	PRICE SENSITIVE	155.67KB	Share
LBT Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	755.69KB	Share
LBT Appendix 4C - quarterly
30/01/20	PRICE SENSITIVE	323.01KB	Share
LBT LBT Receives $1.1 Million R&D Tax Incentive
22/01/20	PRICE SENSITIVE	101.73KB	Share
LBT Presentation at Biotech Showcase Investor Conference
14/01/20	PRICE SENSITIVE	1.52MB	Share
LBT CEO Presentation - AGM 2019
27/11/19	PRICE SENSITIVE	1.42MB	Share
LBT Chairman's Address to Shareholders
27/11/19	PRICE SENSITIVE	109.92KB	Share
LBT Non-Executive Director Retirement
30/10/19	PRICE SENSITIVE	128.69KB	Share
LBT Appendix 4C - quarterly
25/10/19	PRICE SENSITIVE	298.57KB	Share
LBT First European Sale of APAS Independence
21/10/19	PRICE SENSITIVE	145.61KB	Share
LBT LBT Presents at ExchangeSA Conference in Adelaide
26/09/19	PRICE SENSITIVE	2.31MB	Share
LBT MRSA Analysis Module CE Mark Registration
25/09/19	PRICE SENSITIVE	133.87KB	Share
LBT European Union Regulatory Certification & MRSA Study Results
16/09/19	PRICE SENSITIVE	145.9KB	Share
LBT Appendix 4E Full Year Report
29/08/19	PRICE SENSITIVE	141.14KB	Share
LBT Appendix 4C - quarterly
29/07/19	PRICE SENSITIVE	291.44KB	Share
LBT Update on Distributor Appointments
22/07/19	PRICE SENSITIVE	140.02KB	Share
LBT South Australian Government Loan $1.5M Drawdown
27/06/19	PRICE SENSITIVE	131.69KB	Share
LBT First U.S. Clinical Data with APAS Presented at ASM Microbe
24/06/19	PRICE SENSITIVE	658.03KB	Share
LBT US Market Update
19/06/19	PRICE SENSITIVE	132.39KB	Share
LBT Information Required Under ASX Listing Rule 3.10.5A
11/06/19	PRICE SENSITIVE	111.28KB	Share
LBT $5M Oversubscribed Private Placement
05/06/19	PRICE SENSITIVE	1.46MB	Share
LBT Trading Halt
03/06/19	PRICE SENSITIVE	292.92KB	Share
LBT APAS Independence Receives US FDA 510(k) Clearance
20/05/19	PRICE SENSITIVE	442.5KB	Share
LBT Trading Halt
17/05/19	PRICE SENSITIVE	157.96KB	Share
LBT South Australian Government Loan - $1.0M Drawdown
09/05/19	PRICE SENSITIVE	130.71KB	Share

REFRESH

1 2

(20min delay)
Last 1.3¢		Change -0.001(7.14%)		Mkt cap ! $21.47M

Open	High	Low	Value	Volume
1.4¢	1.4¢	1.3¢	$12.8K	950K

Buyers (Bids)

No.	Vol.	Price($)
6	4268596	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	197886	2

View Market Depth

No.	Vol.	Price($)
5	4245520	0.013
3	7333332	0.012
6	806500	0.011
5	1089004	0.010
3	256759	0.009

Price($)	Vol.	No.
0.015	429699	3
0.016	931586	6
0.017	990881	7
0.018	457000	3
0.020	115000	1

Last trade - 14.43pm 20/09/2024 (20 minute delay)


Last 1.3¢		Change -0.001 ( 3.70 %)
Open	High	Low	Volume
1.5¢	1.5¢	1.3¢	662691
Last updated 15.59pm 20/09/2024 ?

LBT (ASX) Chart

LBT INNOVATIONS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available